CompletedNCT00566631
Flexible-dose paliperidone for hospitalized adults with acute schizophrenia
About this title
Read the official source — NCT00566631Researchers studied Paliperidone to find out how it affected psychotic symptoms in people with schizophrenia.
Medication studyAges 18+Multiple countries
Understand this study
What did researchers investigate?
Researchers studied Paliperidone to find out how it affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Zagreb and 29 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJuly 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 294
- Sponsor
- Janssen-Cilag International NV
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, Croatia, Germany, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT00566631
- Official title
Show the full official title
Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedZagreb, Croatia · Dieppe, France · La Charité-sur-Loire, France
27 more locations
- Metz, France
- Augsburg, Germany
- Bonn, Germany
- Mainz, Germany
- Mannheim, Germany
- München, Germany
- Rostock, Germany
- Wasserburg, Germany
- Be-Er Ya-Acov, Israel
- Beersheba, Israel
- Hod HaSharon, Israel
- Pardesiyya, Israel
- Ramat Gan, Israel
- Klaipėda, Lithuania
- Šiauliai, Lithuania
- Vilnius, Lithuania
- Gda Sk Poland, Poland
- Gmina Świecie, Poland
- Lodz, Poland
- Lublin, Poland
- Lubliniec, Poland
- Skąpe, Poland
- Torun, Poland
- Ząbki, Poland
- Bucharest, Romania
- Cluj-Napoca, Romania
- Craiova, Romania
Questions about this study
What did researchers investigate?
Researchers studied Paliperidone to find out how it affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Janssen-Cilag International NV.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...